Recent Finacing
Recent Raise
CDR-Life develops immuno-oncology therapies using proprietary M-gager® antibodies that target intracellular MHC-presented proteins; lead program CDR404 is a dual MAGE‑A4 T‑cell engager, partnered with Boehringer Ingelheim in Europe.
